secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2026-06-29T20:51:57+00:00
Accession:  0001493152-26-031103
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharma reports FY2026 revenue of $148.9M (+77% YoY), operating income $49.1M (+151%)
--------------------------------------------------------------------------------

- Consolidated revenue $148.9M, up $64.8M (77%) vs prior year; operating profit $49.1M, up $29.5M (151%).
- Growth driven by full-year contribution of Lisdexamfetamine, plus launches of Oxycodone Acetaminophen, Naltrexone, and Phentermine tablets.
- Conference call on June 30, 2026 at 11:30 AM EDT; dial-in 1-800-346-7359 (domestic), conference number 98840.
- Stockholders may submit financial questions by 7:00 PM EDT on June 29, 2026 via dianne@elitepharma.com.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315226031103/0001493152-26-031103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315226031103/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-031103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer